LGK 974 (CAS: 1243244-14-5)
|
SKU-Pack Size | Availability | Size | Price | |
EBC51135-1ML | In Stock | 1mL(10mM in DMSO) | €180.70 | |
EBC51135-5MG | In Stock | 5mg | €154.70 | |
EBC51135-10MG | In Stock | 10mg | €258.70 | |
EBC51135-25MG | In Stock | 25mg | €518.70 | |
EBC51135-50MG | In Stock | 50mg | €778.70 |
Please Select The Country You Are In To Find Your Local Distributor. |
Cambiotech | Phone£º+44 (0) 188 448801 | |
Lanwades Business Park, | E-mail£ºinfo@cambiotech.com | |
Ireland | Kobenhavn K, Ireland | Web£ºwww.cambiotech.com |
Product Information | |||||||||||||||||||||
Synonym(s) | NVP-LGK974, WNT974 | ||||||||||||||||||||
Chemical Name | 2-[5-methyl-6-(2-methylpyridin-4-yl)pyridin-3-yl]-N-(5-pyrazin-2-ylpyridin-2-yl)acetamide | ||||||||||||||||||||
Application | LGK 974 is a potent and specific small molecule Porcupine (PORCN) inhibitor | ||||||||||||||||||||
CAS Number | 1243244-14-5 | ||||||||||||||||||||
Purity | ¡Ý98.0% | ||||||||||||||||||||
Molecular Weight | 396.44 | ||||||||||||||||||||
Molecular Formula | C₂₃H₂₀N₆O | ||||||||||||||||||||
SMILES | CC1=C(N=CC(=C1)CC(=O)NC2=NC=C(C=C2)C3=NC=CN=C3)C4=CC(=NC=C4)C | ||||||||||||||||||||
Target & IC50 | PORCN | ||||||||||||||||||||
Solubility | DMSO: 19.8 mg/mL (49.9 mM) | ||||||||||||||||||||
Preparing Stock Solutions |
|
||||||||||||||||||||
Shipping | Gel Pack | ||||||||||||||||||||
Storage | Store at -20¡ãC | ||||||||||||||||||||
Research Use | For Research Use Only. Not Intended for Diagnostic Or Therapeutic Use. |
Product Description | |
LGK 974 is a potent and specific small molecule Porcupine (PORCN) inhibitor. Porcupine (PORCN) is a membrane bound O-acyltransferase that mediates palmitoylation of Wnt family proteins. This step is required for secretion and biologic activity of Wnt proteins, which have roles in embryonic development and cancer. LGK 974 greatly reduces Wnt secretion without decreasing its synthesis and without increasing cytotoxicity. LGK 974 is orally bioavailable in mice and induces tumor regression in mouse breast tumors produced by mammary tumor virus-driven Wnt1 signaling. Interestingly, it can also block carcinogenesis in other Wnt-related tumors at doses that have limited impact on stem cell renewal. |
Specific Protocols | |